1Q26 - Yutrepia Momentum and Positive Cash Flow Continue to Grow. All Eyes Remain on '327 Trial Decisions. Raising PT to $59 from $50.

Research evidence excerpt

1Q26 - Yutrepia Momentum and Positive Cash Flow Continue to Grow. All Eyes Remain on '327 Trial Decisions. Raising PT to $59 from $50.

iagnosed PH-ILD patients, was shared during the R&D Day in October 2025. There were 54 patients

treated with Yutrepia, and 39 completed the 24wk study assessment (15 patients discontinued for various reasons, including

physician decision, protocol violation, lung transplant, or adverse events). As patients titrated their dose over 24wks, thereRESEARCH

were no significant changes seen in tolerability, and daytime cough scores remained stable. No patients discontinued Yutrepia

treatment due to cough at 24wks. At each time point analyzed, over 80% of patients received ≥132.5mcg of Yutrepia, and multiple

patients exceeded 300mcg dose at 24wks (median doses at 8wks, 16wks, and 24wks were 132.5mcg, 159.0mcg, and 185.5mcg,

respectively). Patients assessed at 24wks continued to see an increase in 6MWD from baseline compared to earlier timepoints

(+41.0m vs. +31.5m vs. +21.5m at 24wks, 16wks, and 8wks, respectively).

L606 could address the large unmet need of adequate PK during nighttime hours as a convenient BID inhaled treprostinil Tx.

Current inhaled treprostinil therapies have short half-lives, which require multiple doses throughout the day and leave patients

vulnerable during sleep when skipped doses can allow for increased PVR to return and cause stress on the right ventricle. L606’s

longer half-life and BID dosing could enable coverage throughout the night, which is designed to mimic the steady-state achieved

with parenteral Tx. KOLs have also communicated current dosing regimens could be intrusive and think many patients do not

fully adhere, so BID dosing could improve adherence.